{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:13:12Z","timestamp":1780704792264,"version":"3.54.1"},"reference-count":24,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>\n                    Salivary gland tumors are rare and very heterogeneous types of head and neck cancer. Among them, salivary duct carcinoma (SDC) is one of the most aggressive, with poor prognosis and few recommendations for treatment. Numerous targetable mutations have been described in SDC, especially for Human Epidermal growth factor receptor 2 (HER2), up to 56% according to the literature. This target is interesting due to the development of several forms of anti-HER2 therapy in other cancers. Finally, the antibody-drug conjugate trastuzumab-deruxtecan (T-Dxd) significantly improves progression-free survival and objective response rate, with tolerable side effects. Few data have been published concerning anti-HER2 therapies for SDC, mainly concerning T-Dxd, most of the studies described treatment with docetaxel or trastuzumab alone. As patients with SDC are often young and without comorbidities, they receive a few different treatments. That is why case reports about patients with SDC treated by T-Dxd can facilitate molecular testing of these tumors and improve our knowledge about this rare disease. This report describes a 44-year-old man with HER2-positive locally advanced SDC who experienced disease progression just after surgery. Molecular analysis showed positive androgen receptors,\n                    <jats:italic toggle=\"yes\">MLH1<\/jats:italic>\n                    mutation, and HER2 positivity. He had received several different treatments, including endocrine therapy, chemotherapy, immunotherapy, and anti-HER2 therapy. The longest duration of treatment was observed with T-Dxd: 13\u2009months, allowing local treatment of localized progression (cervical lymph nodes, bone metastasis) at the same time. This report and other published data highlight the need for better implementation of recommendations for molecular testing regarding a rare and aggressive salivary tumor. In addition, these data should increase the development of clinical research in this small patient population.\n                  <\/jats:p>","DOI":"10.1177\/17588359251334071","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T09:28:04Z","timestamp":1748942884000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Trastuzumab-deruxtecan shows interesting disease control in a multitreated patient with ERBB2 amplified parotid carcinoma, a case report"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3147-1350","authenticated-orcid":false,"given":"Camille","family":"Evrard","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Poitiers University Hospital and ProDicET, UR 24144, 2 rue de la mil\u00e9trie, Poitiers 86000, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Goujon","sequence":"additional","affiliation":[{"name":"Department of Pathology, Poitiers University Hospital, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Villalva","sequence":"additional","affiliation":[{"name":"Biology of Cancer Laboratory, Poitiers University Hospital, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Bainaud","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Poitiers University Hospital, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41199-016-0011-z"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.12.035"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0007"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100602"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-024-00750-w"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.173"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.25194"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2019.08.009"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00545"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00725-0"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02420-5"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02992-x"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00215-2"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.6037"},{"key":"e_1_3_4_17_2","article-title":"Excellent response to fam-trastuzumab deruxtecan for HER2-positive salivary duct carcinoma with CNS metastasis: a case report","volume":"6","author":"Gazola AA","year":"2022","unstructured":"Gazola AA, Wong D, Chin R, et al. Excellent response to fam-trastuzumab deruxtecan for HER2-positive salivary duct carcinoma with CNS metastasis: a case report. JCO Precis Oncol 2022; 6: e2200399.","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106566"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.7089"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad181"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv611"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31090419"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106612"},{"key":"e_1_3_4_24_2","volume-title":"Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent\/metastatic salivary gland cancer: results from the MYTHOS trial","author":"Ichiro K","unstructured":"Ichiro K, Satoshi K, Yoshitaka H. Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent\/metastatic salivary gland cancer: results from the MYTHOS trial. Presented at the ESMO Congress 2024, 13\u201317 September 2024, Barcelona, Spain."},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.04.026"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251334071","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251334071","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251334071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:32:06Z","timestamp":1777588326000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251334071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":24,"alternative-id":["10.1177\/17588359251334071"],"URL":"https:\/\/doi.org\/10.1177\/17588359251334071","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"17588359251334071"}}